In July 2015, FEB acquired a 40% equity stake in ADCAN Pharma LLC (ADCAN). ADCAN is an Abu Dhabi based company and will primarily comprise medicine production. This is an investment opportunity to diversify FEB’s investments in the health sector in UAE.